Management of portal hypertension before and after liver transplantation

Lukas W. Unger, Gabriela A. Berlakovich, Michael Trauner, Thomas Reiberger – 28 July 2017 – Orthotopic liver transplantation (OLT) represents a curative treatment option for end‐stage liver disease (ESLD). Although epidemiology of ESLD has recently changed due to the rising prevalence of nonalcoholic fatty liver disease and the decreased burden of hepatitis C virus infections due to highly effective antiviral regimens, the management of portal hypertension (PHT) remains a clinical challenge in the pre‐ and post‐OLT setting.

Outcome of liver transplantation in patients with prior bariatric surgery

Mohamed Safwan, Kelly M. Collins, Marwan S. Abouljoud, Reena Salgia – 28 July 2017 – Nonalcoholic fatty liver disease is becoming the leading cause of disease resulting in liver transplantation (LT). As a result of this trend, more LT candidates are presenting with prior history of bariatric surgery (BS). Over the last decade, 960 patients underwent LT at our institution; 11 (1.1%) had prior BS. The most common type of BS was Roux‐en‐Y gastric bypass (n = 9) with 1 sleeve gastrectomy and 1 jejunoileal bypass.

Hepatocyte‐derived exosomes promote T follicular regulatory cell expansion during hepatitis C virus infection

Dustin A. Cobb, Ok‐Kyung Kim, Lucy Golden‐Mason, Hugo R. Rosen, Young S. Hahn – 27 July 2017 – Hepatitis C virus (HCV) is a global health concern that can cause severe liver disease, such as cirrhosis and hepatocellular carcinoma. Control of HCV requires vigorous T‐cell responses, yet CD4+ T cells in chronic HCV patients are dysfunctional. T follicular regulatory (Tfr) cells are a subset of regulatory T cells that suppress T follicular helper (Tfh) cells and the generation of high affinity antibody‐producing B cells.

Subscribe to